Literature DB >> 12445868

Role of poly(ADP-ribose) polymerase activation in endotoxin-induced cardiac collapse in rodents.

Pál Pacher1, Attila Cziráki, Jon G Mabley, Lucas Liaudet, Lajos Papp, Csaba Szabó.   

Abstract

Reactive oxygen and nitrogen species are overproduced in the cardiovascular system during circulatory shock. Oxidant-induced cell injury involves the activation of poly(ADP-ribose) polymerase (PARP). Using a dual approach of PARP-1 suppression, by genetic deletion or pharmacological inhibition with the new potent phenanthridinone PARP inhibitor PJ34 [the hydrochloride salt of N-(oxo-5,6-dihydro-phenanthridin-2-yl)-N,N-dimethylacetamide], we studied whether the impaired cardiac function in endotoxic shock is dependent upon the PARP pathway. Escherichia coli endotoxin (lipopolysaccharide, LPS) at 55 mg/kg, i.p., induced a severe depression of the systolic and diastolic contractile function, tachycardia, and a reduction in mean arterial blood pressure in both rats and mice. Treatment with PJ34 significantly improved cardiac function and increased the survival of rodents. In addition, LPS-induced depression of left ventricular performance was significantly less pronounced in PARP-1 knockout mice (PARP(-/-)) as compared with their wild-type littermates (PARP(+/+)). Thus, PARP activation in the cardiovascular system is an important contributory factor to the cardiac collapse and death associated with endotoxin shock. Copyright 2002 Elsevier Science Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12445868     DOI: 10.1016/s0006-2952(02)01421-1

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  13 in total

1.  Cannabinoid antagonist SR-141716 inhibits endotoxic hypotension by a cardiac mechanism not involving CB1 or CB2 receptors.

Authors:  Sándor Bátkai; Pál Pacher; Zoltán Járai; Jens A Wagner; George Kunos
Journal:  Am J Physiol Heart Circ Physiol       Date:  2004-04-01       Impact factor: 4.733

2.  Beneficial effects of a novel ultrapotent poly(ADP-ribose) polymerase inhibitor in murine models of heart failure.

Authors:  Pál Pacher; Lucas Liaudet; Jon G Mabley; Attila Cziráki; György Haskó; Csaba Szabó
Journal:  Int J Mol Med       Date:  2006-02       Impact factor: 4.101

Review 3.  Pathophysiological roles of peroxynitrite in circulatory shock.

Authors:  Csaba Szabó; Katalin Módis
Journal:  Shock       Date:  2010-09       Impact factor: 3.454

Review 4.  Nitrosative stress and pharmacological modulation of heart failure.

Authors:  Pal Pacher; Richard Schulz; Lucas Liaudet; Csaba Szabó
Journal:  Trends Pharmacol Sci       Date:  2005-06       Impact factor: 14.819

5.  Single dose treatment with PARP-inhibitor INO-1001 improves aging-associated cardiac and vascular dysfunction.

Authors:  Tamás Radovits; Leila Seres; Domokos Gero; Irina Berger; Csaba Szabó; Matthias Karck; Gábor Szabó
Journal:  Exp Gerontol       Date:  2007-02-20       Impact factor: 4.032

Review 6.  Role of poly(ADP-ribose) polymerase-1 activation in the pathogenesis of diabetic complications: endothelial dysfunction, as a common underlying theme.

Authors:  Pál Pacher; Csaba Szabó
Journal:  Antioxid Redox Signal       Date:  2005 Nov-Dec       Impact factor: 8.401

7.  Nucling, a novel protein associated with NF-κB, regulates endotoxin-induced apoptosis in vivo.

Authors:  Sun Mi Kim; Takashi Sakai; Huy Van Dang; Nam Hoang Tran; Koji Ono; Kazunori Ishimura; Kiyoshi Fukui
Journal:  J Biochem       Date:  2012-10-15       Impact factor: 3.387

Review 8.  Therapeutic applications of PARP inhibitors: anticancer therapy and beyond.

Authors:  Nicola J Curtin; Csaba Szabo
Journal:  Mol Aspects Med       Date:  2013-01-29

Review 9.  Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors.

Authors:  Pál Pacher; Csaba Szabó
Journal:  Cardiovasc Drug Rev       Date:  2007

10.  A new, potent poly(ADP-ribose) polymerase inhibitor improves cardiac and vascular dysfunction associated with advanced aging.

Authors:  Pál Pacher; Anne Vaslin; Rita Benko; Jon G Mabley; Lucas Liaudet; György Haskó; Anita Marton; Sándor Bátkai; Márk Kollai; Csaba Szabó
Journal:  J Pharmacol Exp Ther       Date:  2004-06-22       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.